| EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib W Pao, V Miller, M Zakowski, J Doherty, K Politi, I Sarkaria, B Singh, ... Proceedings of the National Academy of Sciences 101 (36), 13306-13311, 2004 | 5367 | 2004 |
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain W Pao, VA Miller, KA Politi, GJ Riely, R Somwar, MF Zakowski, MG Kris, ... PLoS medicine 2 (3), e73, 2005 | 4281 | 2005 |
| Comprehensive genomic characterization of squamous cell lung cancers Cancer Genome Atlas Research Network Nature 489 (7417), 519, 2012 | 3649 | 2012 |
| Somatic mutations affect key pathways in lung adenocarcinoma L Ding, G Getz, DA Wheeler, ER Mardis, MD McLellan, K Cibulskis, ... Nature 455 (7216), 1069-1075, 2008 | 3095 | 2008 |
| Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers HA Yu, ME Arcila, N Rekhtman, CS Sima, MF Zakowski, W Pao, MG Kris, ... Clinical cancer research 19 (8), 2240-2247, 2013 | 2589 | 2013 |
| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer DAE Cross, SE Ashton, S Ghiorghiu, C Eberlein, CA Nebhan, PJ Spitzler, ... Cancer discovery 4 (9), 1046-1061, 2014 | 2088 | 2014 |
| Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing M Imielinski, AH Berger, PS Hammerman, B Hernandez, TJ Pugh, ... Cell 150 (6), 1107-1120, 2012 | 1976 | 2012 |
| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib J Bean, C Brennan, JY Shih, G Riely, A Viale, L Wang, D Chitale, N Motoi, ... Proceedings of the National Academy of Sciences 104 (52), 20932-20937, 2007 | 1949 | 2007 |
| KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib W Pao, TY Wang, GJ Riely, VA Miller, Q Pan, M Ladanyi, MF Zakowski, ... PLoS medicine 2 (1), e17, 2005 | 1943 | 2005 |
| ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers K Bergethon, AT Shaw, SH Ignatius Ou, R Katayama, CM Lovly, ... Journal of clinical oncology 30 (8), 863-870, 2012 | 1941 | 2012 |
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ... Jama 311 (19), 1998-2006, 2014 | 1782 | 2014 |
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104-1110, 2012 | 1461 | 2012 |
| New driver mutations in non-small-cell lung cancer W Pao, N Girard The lancet oncology 12 (2), 175-180, 2011 | 1447 | 2011 |
| Characterizing the cancer genome in lung adenocarcinoma BA Weir, MS Woo, G Getz, S Perner, L Ding, R Beroukhim, WM Lin, ... Nature 450 (7171), 893-898, 2007 | 1275 | 2007 |
| Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer W Pao, J Chmielecki Nature Reviews Cancer 10 (11), 760-774, 2010 | 1221 | 2010 |
| American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer CG Azzoli, S Baker Jr, S Temin, W Pao, T Aliff, J Brahmer, DH Johnson, ... Journal of clinical oncology 27 (36), 6251, 2009 | 1055 | 2009 |
| Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ... Science translational medicine 2 (62), 62ra93-62ra93, 2010 | 1007 | 2010 |
| Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors MN Balak, Y Gong, GJ Riely, R Somwar, AR Li, MF Zakowski, A Chiang, ... Clinical cancer research 12 (21), 6494-6501, 2006 | 971 | 2006 |
| Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer D Jackman, W Pao, GJ Riely, JA Engelman, MG Kris, PA Jänne, T Lynch, ... Journal of clinical oncology 28 (2), 357, 2010 | 954 | 2010 |
| Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer VA Miller, MG Kris Oncology Times 26 (11), 69-70, 2004 | 954 | 2004 |
